Single dose use of cd20-specific binding molecules

Details Single dose use of cd20-specific binding molecules Single dose use of cd20-specific binding molecules

A - Human Necessities

61

K

A61K 39/395 (2006.01) A61P 37/06 (2006.01)

Patent

CA 2616386

The present invention provides materials and methods for treatment of diseases involving aberrant B-cell activity using a single dose of CD20-specific binding molecule.

La présente invention a trait à des substances et des procédés pour le traitement de maladies impliquant l'activité aberrante de lymphocyte B mettant en oeuvre une dose unique de molécule de liaison spécifique au CD20.

Affiliated with

Also associated with

Rating

Single dose use of cd20-specific binding molecules does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Single dose use of cd20-specific binding molecules, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Single dose use of cd20-specific binding molecules will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1596422